Home / Research / Publications / Clinical outcomes and characterization of HER2 alterations in Non Small Cell Lung Cancer

Publications

Clinical outcomes and characterization of HER2 alterations in Non Small Cell Lung Cancer

Background

Subsets of NSCLC carry alterations in the human epidermal growth factor receptor 2 (HER2) gene such as mutations (mt), amplification (amp), and protein overexpression. These alterations reflect distinct patient (pt) populations and disease biology, translating to variable outcomes with immunotherapy +/- chemotherapy. HER2-directed therapies have shown significant efficacy for HER2 mt and to a lesser extent HER2 overexpression NSCLC. We describe the genomic landscape of HER2-altered NSCLC in a large cohort of tumors from the Caris database and explore patient outcomes.

Download Publication
Learn More
Name(Required)